Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5340)	7/16/1998 6:28:00 PM
From: Vector1	Read Replies (1) \| Respond to of 9719

Its amazing what you can find digging through SEC docs. The following is from CLTR's recenly filed reg statement. The expanded use permit by the FDA is quite significant in terms of what Bexxars label might look like when approved. -- In addition, a Phase II dose escalation clinical trial has commenced at the University of Nebraska for the combined use of radiolabeled B-1 Antibody and standard chemotherapy as preparation for autologous bone marrow transplant. Other Clinical Trials and Developments. The Company is also conducting a Phase II multi-center investigational trial in patients previously treated with Bexxar. This open label trial include low-, intermediate- and high-grade NHL patients who have relapsed from their initial Bexxar treatment. The Company has received initial approval from the FDA to commence an expanded access program. Through this program, additional patients may be treated with Bexxar during the period prior to FDA marketing approval.

To: Biomaven who wrote (5340)	7/16/1998 8:18:00 PM
From: John Zwiener	Read Replies (2) \| Respond to of 9719

Peter, I don't think it's a matter of Roche BMG jeopardizing an important relationship, at least in their minds. I think Roche/BMG sees it as aggressive business practice. I think it is common for big companies to overplay their licenses from small companies because they usually win. But I don't think they expected Igen to raise 25 million to fight them, and to pull the moves they have. It's important to realize that Roche is claiming revenue on the electsys instruments that would be money losing, but the continue to push forward rapidly with it's development and deployment. Also, it points out that there is a lot of money at stake, or their wouldn't be this fight. Your point about short sellers is interesting since it is over 1 million out of 17 million shares. I understand most of this is the convertible share holders and this may have accounted for the recent drop to 30. But it seems that Soros was still adding at these levels, so I don't know the significance of the short sellers. It seems that most of the biotechs have seen increasing short selling, maybe it's partially a general industry play.